Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Moore

Showing results (1131-1140 of 1,421) with videos related to

Pageof 143
Sort By:
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Water Resources Research|November 25, 2024
Combining a Multi-Lake Model Ensemble and a Multi-Domain CORDEX Climate Data Ensemble for Assessing Climate Change Impacts on Lake SevanMuhammed Shikhani, Johannes Feldbauer, Robert Ladwig, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 25, 2015
AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in MiceJenny L Wiley, Julie A Marusich, Timothy W Lefever, et al.
Plos One|June 1, 2018
Unexpected timely fracture union in matrix metalloproteinase 9 deficient miceMasato Yuasa, Masanori Saito, Cesar Molina, et al.
Gynecologic Oncology|September 17, 2019
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancerLauren E Dockery, Abby R Rubenstein, Kai Ding, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
JCI Insight|December 8, 2021
Plasmin drives burn-induced systemic inflammatory response syndromeBreanne H Y Gibson, Colby C Wollenman, Stephanie N Moore-Lotridge, et al.
Molecular Cancer Therapeutics|July 21, 2018
Inhibition of BMI1, a Therapeutic Approach in Endometrial CancerMegan Buechel, Anindya Dey, Shailendra Kumar Dhar Dwivedi, et al.
Public Health Nutrition|September 24, 2014
Communication of scientific uncertainty: international case studies on the development of folate and vitamin D Dietary Reference ValuesKerry A Brown, Liesbeth de Wit, Lada Timotijevic, et al.
Gynecologic Oncology|December 14, 2011
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?E K Nugent, E A Bishop, C A Mathews, et al.
Pageof 143

Showing results (1131-1140 of 1,421) with videos related to

Sort By:
Pageof 143
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Water Resources Research|November 25, 2024
Combining a Multi-Lake Model Ensemble and a Multi-Domain CORDEX Climate Data Ensemble for Assessing Climate Change Impacts on Lake SevanMuhammed Shikhani, Johannes Feldbauer, Robert Ladwig, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 25, 2015
AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in MiceJenny L Wiley, Julie A Marusich, Timothy W Lefever, et al.
Plos One|June 1, 2018
Unexpected timely fracture union in matrix metalloproteinase 9 deficient miceMasato Yuasa, Masanori Saito, Cesar Molina, et al.
Gynecologic Oncology|September 17, 2019
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancerLauren E Dockery, Abby R Rubenstein, Kai Ding, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
JCI Insight|December 8, 2021
Plasmin drives burn-induced systemic inflammatory response syndromeBreanne H Y Gibson, Colby C Wollenman, Stephanie N Moore-Lotridge, et al.
Molecular Cancer Therapeutics|July 21, 2018
Inhibition of BMI1, a Therapeutic Approach in Endometrial CancerMegan Buechel, Anindya Dey, Shailendra Kumar Dhar Dwivedi, et al.
Public Health Nutrition|September 24, 2014
Communication of scientific uncertainty: international case studies on the development of folate and vitamin D Dietary Reference ValuesKerry A Brown, Liesbeth de Wit, Lada Timotijevic, et al.
Gynecologic Oncology|December 14, 2011
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?E K Nugent, E A Bishop, C A Mathews, et al.
Pageof 143